Table 3.

Randomized studies of gemcitabine and S-1 therapy vs gemcitabine for metastatic or locally advanced pancreatic cancer

Study	Treatment	n	ORR	PFS (mo)	MST (mo)
GEST[10]	GS	275	29%b	5.7b	10.1
(PIII)	S-1	280	21%a	3.8c	9.7d
	GEM	277	13%	4.1	8.8
GEMSAP[24]	GS	53	18.9%	5.4a	13.5
(rPII)	GEM	53	9.4%	3.6	8.8
JACCRO PC-01[25] (rPII)	GS	53	28.3%b	6.15b	13.7a
	GEM	59	6.8%	3.78	8.0
Sudo et al[26]	GS	51	21.6%a	5.3a	8.6
	GEM	50	6.0%	3.8	8.6

^aP < 0.05 vs GEM;

^bP < 0.01 vs GEM;

^cP < 0.05 non-inferiority to GEM;

^dP < 0.01 non-inferiority to GEM. PFS: Progression-free survival; MST: Median survival time; GEM: Gemcitabine; GS: Gemcitabine and S-1; ORR: Objective response rate.